352 related articles for article (PubMed ID: 30878066)
1. Early efficacy and safety of Bedaquiline and Delamanid given together in a "Salvage Regimen" for treatment of drug-resistant tuberculosis.
Sarin R; Vohra V; Singla N; Singla R; Puri MM; Munjal SK; Khalid UK; Myneedu VP; Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):184-188. PubMed ID: 30878066
[TBL] [Abstract][Full Text] [Related]
2. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
3. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G; Mohr E; Laxmeshwar C; Hewison C; Hughes J; Jonckheere S; Khachatryan N; De Avezedo V; Egazaryan L; Shroufi A; Kalon S; Cox H; Furin J; Isaakidis P
Lancet Infect Dis; 2018 May; 18(5):536-544. PubMed ID: 29452942
[TBL] [Abstract][Full Text] [Related]
4. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
5. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia.
Soedarsono S; Mertaniasih NM; Kusmiati T; Permatasari A; Subay S; Adiono SH
Int J Mycobacteriol; 2024 Apr; 13(2):140-146. PubMed ID: 38916383
[TBL] [Abstract][Full Text] [Related]
7. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
8. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Franke MF; Khan P; Hewison C; Khan U; Huerga H; Seung KJ; Rich ML; Zarli K; Samieva N; Oyewusi L; Nair P; Mudassar M; Melikyan N; Lenggogeni P; Lecca L; Kumsa A; Khan M; Islam S; Hussein K; Docteur W; Chumburidze N; Berikova E; Atshemyan H; Atwood S; Alam M; Ahmed S; Bastard M; Mitnick CD
Am J Respir Crit Care Med; 2021 Jan; 203(1):111-119. PubMed ID: 32706644
[No Abstract] [Full Text] [Related]
9. Effect of Bedaquiline and Delamanid Pharmacokinetics on Sputum Culture Conversion and Adverse Events in Drug-Resistant Tuberculosis.
Bhatnagar AK; Hemanthkumar AK; Muthu Vijayalakshmi M; Vohra V; Padmapriyadarsini C; Ramesh PM; Taneja G; Chavan VN; Jeyadeepa B; Bhui NK; Solanki R
Ther Drug Monit; 2024 Jun; 46(3):363-369. PubMed ID: 38161267
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
[No Abstract] [Full Text] [Related]
11. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
Mikiashvili L; Kempker RR; Chakhaia TS; Bablishvili N; Avaliani Z; Lomtadze N; Schechter MC; Kipiani M
Clin Infect Dis; 2024 Apr; 78(4):1043-1052. PubMed ID: 37962987
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
Byun JH; Park JA; Kang HR; Shin JY; Lee EK
Clin Drug Investig; 2016 Nov; 36(11):957-968. PubMed ID: 27465204
[TBL] [Abstract][Full Text] [Related]
14. Delamanid for multidrug-resistant pulmonary tuberculosis.
Gler MT; Skripconoka V; Sanchez-Garavito E; Xiao H; Cabrera-Rivero JL; Vargas-Vasquez DE; Gao M; Awad M; Park SK; Shim TS; Suh GY; Danilovits M; Ogata H; Kurve A; Chang J; Suzuki K; Tupasi T; Koh WJ; Seaworth B; Geiter LJ; Wells CD
N Engl J Med; 2012 Jun; 366(23):2151-60. PubMed ID: 22670901
[TBL] [Abstract][Full Text] [Related]
15. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
16. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
[TBL] [Abstract][Full Text] [Related]
17. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
[No Abstract] [Full Text] [Related]
19. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
[TBL] [Abstract][Full Text] [Related]
20. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]